Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) is one of 842 public companies in the “Biotechnology” industry, but how does it contrast to its rivals? We will compare Alaunos Therapeutics to related businesses based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, risk, dividends and profitability.
Volatility & Risk
Alaunos Therapeutics has a beta of -1.02, indicating that its share price is 202% less volatile than the S&P 500. Comparatively, Alaunos Therapeutics’ rivals have a beta of -1.84, indicating that their average share price is 284% less volatile than the S&P 500.
Earnings and Valuation
This table compares Alaunos Therapeutics and its rivals revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Alaunos Therapeutics | $3,000.00 | -$4.18 million | -0.87 |
| Alaunos Therapeutics Competitors | $764.04 million | $10.42 million | -17.98 |
Alaunos Therapeutics’ rivals have higher revenue and earnings than Alaunos Therapeutics. Alaunos Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Profitability
This table compares Alaunos Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Alaunos Therapeutics | N/A | -286.18% | -174.96% |
| Alaunos Therapeutics Competitors | -12,519.20% | -215.47% | -31.42% |
Insider & Institutional Ownership
27.7% of Alaunos Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 16.1% of Alaunos Therapeutics shares are held by company insiders. Comparatively, 13.2% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Analyst Recommendations
This is a summary of recent ratings for Alaunos Therapeutics and its rivals, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Alaunos Therapeutics | 1 | 1 | 1 | 0 | 2.00 |
| Alaunos Therapeutics Competitors | 9959 | 15361 | 45766 | 1602 | 2.54 |
As a group, “Biotechnology” companies have a potential upside of 114.70%. Given Alaunos Therapeutics’ rivals stronger consensus rating and higher probable upside, analysts clearly believe Alaunos Therapeutics has less favorable growth aspects than its rivals.
Summary
Alaunos Therapeutics rivals beat Alaunos Therapeutics on 9 of the 13 factors compared.
Alaunos Therapeutics Company Profile
Alaunos Therapeutics was a biotechnology company focused on developing engineered T-cell therapies for cancer. Its research centered on T-cell receptor (TCR) therapies designed to help a patient’s immune cells recognize and attack tumors. The company’s main program investigated genetically modified T cells targeting cancer-associated mutations, including mutations in the KRAS gene, in patients with solid tumors. Its approach used a library of TCRs intended to recognize different tumor mutations.
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
